The University of Queensland

Histone deacetylase inhibitors can inhibit tumour growth via induction of an anti-tumour immune response (2008–2009)

Abstract:

Conventional anti-cancer therapies have many debilitating side effects, including suppressing the immune system which has demonstrated anti-cancer activity. New chemotherapeutic drugs are more targeted with fewer side effects. Consequently, it is possible to combine the benefits of chemotherapy and immunotherapy. If successful, we will determine how anti-cancer treatment with these drugs can be optimised to improve curative outcomes.

Grant type:

Cancer Council Queensland

Researchers:

• 

  Professor Brian Gabrielli

  Honorary Professor
  

  Mater Research Institute-UQ

  Faculty of Medicine

• 

  Associate Professor Graham Leggatt

  Associate Professor in Immunology
  

  Frazer Institute

  Faculty of Medicine

  Director (Research Training)
  

  Research Strategy and Support (Medicine)

  Faculty of Medicine

Funded by:

Cancer Council Queensland